Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
NOVARTIS NEW ZEALAND LIMITED,Ofatumumab,Relapsing Remitting Multiple Sclerosis (MS),Ofatumumab (KESIMPTA),Community and Hospital,Nervous System
